Unilab Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Ebitda 88.24%
- Net Worth -25.00%
- Total Assets -1.85%
About Unilab Pharma
Unilab Pharma Private Limited (UPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 March 2017 (Seven years and 11 months 11 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Vora, Dipak Vora, and Smita Vora serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239MH2017PTC292543
- Company No.
292543
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Unilab Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Vora  | Director | 16-Mar-2017 | Current |
| Dipak Vora | Director | 16-Mar-2017 | Current |
| Smita Vora | Director | 16-Mar-2017 | Current |
Financial Performance of Unilab Pharma.
Unilab Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unilab Pharma?
In 2019, Unilab Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Unilab Chemicals And Pharmaceuticals Private LimitedRahul Vora, Dipak Vora and 1 more are mutual person
Prathmesh Dyechem Private LimitedRahul Vora, Dipak Vora and 1 more are mutual person
- Zen Chemicals Private Limited
Rahul Vora, Dipak Vora and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unilab Pharma?
Unlock and access historical data on people associated with Unilab Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unilab Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unilab Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.